Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with -$56.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 29.73% to -$56.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$209.2 million, a 45.79% decrease, with the full-year FY2024 number at -$160.9 million, down 59.53% from a year prior.
  • Net Income towards Common Stockholders was -$56.9 million for Q3 2025 at 4D Molecular Therapeutics, down from -$54.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$7.6 million in Q2 2021 to a low of -$56.9 million in Q3 2025.
  • A 5-year average of -$31.6 million and a median of -$28.7 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: surged 60.08% in 2023, then tumbled 327.49% in 2024.
  • 4D Molecular Therapeutics' Net Income towards Common Stockholders stood at -$25.1 million in 2021, then dropped by 9.15% to -$27.4 million in 2022, then decreased by 17.91% to -$32.3 million in 2023, then tumbled by 53.86% to -$49.7 million in 2024, then dropped by 14.51% to -$56.9 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Net Income towards Common Stockholders are -$56.9 million (Q3 2025), -$54.7 million (Q2 2025), and -$48.0 million (Q1 2025).